Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 17, 2004; DOI: 10.1124/jpet.104.067587
0022-3565/04/3111-411-419$20.00
JPET 311:411-419, 2004
CARDIOVASCULAR
Characterization of Cannabinoid Modulation of Sensory Neurotransmission in the Rat Isolated Mesenteric Arterial Bed
Marnie Duncan,
David A. Kendall, and
Vera Ralevic
School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham, United Kingdom
The present study investigated the effects of different classes of cannabinoid (CB) receptor ligands on sensory neurotransmission in the rat isolated mesenteric arterial bed. Electrical field stimulation of the mesenteric bed evoked frequency-dependent vasorelaxation due to the activation of capsaicin-sensitive sensory nerves and release of calcitonin gene-related peptide (CGRP). The CB1/CB2 cannabinoid agonists WIN55,212 [(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone] and CP55,940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol] (0.011 µM) attenuated sensory neurogenic relaxation in a concentration-dependent manner. At 0.1 µM, WIN55,212 and CP55,940 were largely ineffective in the presence of the CB1 antagonists SR141716A [N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichloro phenyl)-4-methyl-3-pyrazole-carboxamide] and LY320135 [[6-methoxy-2-(4-methoxyphenyl)benzo[b]-thien-3-yl][4-cyanophenyl] methanone] (1 µM), but their inhibitory actions remained in the presence of the CB2-selective antagonist SR144528 [N-[1S)-endo-1,3,3,-trimetyl bicyclo [2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide] (1 µM). The CB1/CB2 agonist
9-tetrahydrocannabinol (THC) (1 µM) attenuated sensory neurogenic relaxations, as did the CB2 agonist JWH-015 [(2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone]. The inhibitory actions of both THC and JWH-015 were still evident in the presence of SR141716A (1 µM) and SR144528 (1 µM). None of the cannabinoid agonists investigated had an effect on vasorelaxation elicited by exogenous CGRP, indicating a prejunctional mechanism. These data demonstrate that different classes of cannabinoid agonists attenuate sensory neurotransmission via a prejunctional site and provide evidence for mediation by a CB1 and/or a non-CB1/CB2 receptor.
Received March 10, 2004;
accepted June 15, 2004.
Address correspondence to: Dr. V. Ralevic, School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK. E-mail: vera.ralevic{at}nottingham.ac.uk
This article has been cited by other articles:

|
 |

|
 |
 
B. B. Yao, G. Hsieh, A. V. Daza, Y. Fan, G. K. Grayson, T. R. Garrison, O. El Kouhen, B. A. Hooker, M. Pai, E. J. Wensink, et al.
Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging
J. Pharmacol. Exp. Ther.,
January 1, 2009;
328(1):
141 - 151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Akopian, N. B. Ruparel, A. Patwardhan, and K. M. Hargreaves
Cannabinoids Desensitize Capsaicin and Mustard Oil Responses in Sensory Neurons via TRPA1 Activation
J. Neurosci.,
January 30, 2008;
28(5):
1064 - 1075.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Jeske, A. M. Patwardhan, N. Gamper, T. J. Price, A. N. Akopian, and K. M. Hargreaves
Cannabinoid WIN 55,212-2 Regulates TRPV1 Phosphorylation in Sensory Neurons
J. Biol. Chem.,
October 27, 2006;
281(43):
32879 - 32890.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.